Evidence map›Paper›PMID 42454064›Full record

ArticleFrontiers in immunology2026

Systemic skewing of peripheral blood leukocyte composition in neurofibromatosis type 1.

Yoshimasa Nobeyama, Satoko Imai, Minako Ogawa-Tominaga, Akihiko Asahina

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yoshimasa NobeyamaDepartment of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Satoko ImaiDepartment of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Minako Ogawa-TominagaDepartment of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Akihiko AsahinaDepartment of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The present study aimed to characterize neurofibromatosis type 1 (NF1)-associated alterations in peripheral white blood cell differentials, focusing on overall patterns and sex-related differences. Methods: We analyzed 225 Japanese patients with NF1 (78 males, 147 females) and 87 controls without NF1 (50 males, 37 females). Within each sex, NF1 and control groups were age-matched. Z-scores were calculated to normalize for sex-specific variation. Results: In patients with NF1, Z-scores for the percentages of neutrophils, monocytes, and basophils were increased, whereas those for lymphocytes and eosinophils were decreased. These trends were consistent across both sexes, indicating robust disease-associated alterations. Additional sex-related differences were observed: males showed greater neutrophil increases and more pronounced lymphocyte reductions, whereas females exhibited greater monocyte increases and more marked eosinophil reductions. Conclusion: NF1 is associated with systemic skewing of peripheral immune cell composition, characterized by expansion of the non-type 2/innate component, relative uncoupling of the type 2-associated component, and reduction of the lymphoid component. These findings provide a conceptual basis for understanding NF1 pathobiology, disease heterogeneity, and sex-related differences, including tumor-associated immune environments.

Indexed as

LeukocytesNeurofibromatosis 1AdolescentAdultChildEosinophilsFemaleHumansLeukocyte CountMaleMiddle AgedSex FactorsYoung AdultbasophileosinophillymphocytemonocyteneutrophilNF1type 2 immunity

Identifiers

PMID42454064
PMCPMC13364682

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.